Form 4: Gilead Sciences Executive Deborah H. Telman Reports Stock Transactions

EVP Deborah H. Telman reports acquisition and disposal of Gilead Sciences stock and derivative securities.

Summary

• On March 10, 2024, Deborah H. Telman, EVP, Corporate Affairs & GC of Gilead Sciences, Inc., reported transactions involving the company's stock.
• Telman acquired 2,555 shares of common stock through the vesting of restricted stock units.
• She also disposed of 846 shares to cover tax obligations at a price of $75.12 per share.
• Following these transactions, Telman directly owns 13,757 shares of common stock.
• Telman also acquired 54,980 non-qualified stock options and 10,815 restricted stock units.
• She now holds 29,268 restricted stock units and 54,980 non-qualified stock options.
• The non-qualified stock options are exercisable beginning March 10, 2024, and expire on March 10, 2034.
• The restricted stock units vest over four years, with 25% vesting on the first anniversary and the remainder vesting quarterly.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing of stock transactions by an executive. The acquisition of stock options and units is a positive sign, but the disposal of shares for tax obligations is a neutral event.

Positives

• The acquisition of stock options and restricted stock units suggests continued alignment of the executive's interests with the company's long-term performance.

Negatives

• The disposal of shares to cover tax obligations, while common, slightly reduces the executive's direct holdings.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with shareholder value, a common practice among companies like Amgen, Pfizer, and Johnson & Johnson.
• The vesting schedules of these equity grants are fairly standard, with a four-year vesting period being a typical benchmark.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding executive compensation and stock ownership.

Key Dates